Back to Search Start Over

Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants

Authors :
Thierry Huby
Maria Teresa Catanese
Martine Moreau
Giacomo Paonessa
Alfredo Nicosia
Alessandra Vitelli
Charles M. Rice
Jonathan K. Ball
Riccardo Cortese
Helenia Ansuini
Rita Graziani
Catanese, Mt
Ansuini, H
Graziani, R
Huby, T
Moreau, M
Ball, Jk
Paonessa, G
Rice, Cm
Cortese, R
Vitelli, A
Nicosia, Alfredo
Laboratory of Virology and Infectious Disease
Rockefeller University [New York]-Center for the Study of Hepatitis C
Istituto di Ricerche di Biologia Molecolare P. Angeletti
Dyslipidémies, inflammation et athérosclérose dans les maladies métaboliques
Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Service d’Endocrinologie, Métabolisme et Prévention des Risques Cardio-Vasculaires [CHU Pitié-Salpêtrière]
CHU Pitié-Salpêtrière [AP-HP]
Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Institute of Infection, Immunity, and Inflammation
University of Nottingham, UK (UON)
CEINGE
Okairos
This work was supported by funding from the European Union (grants QLK2-CT-2001-01120 and MRTN-CT-2006-035599) and PHS grant R01 AI072613. M.T.C. was supported by a Women & Science fellowship.
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Chapman, John
Service d'Endocrinologie, Métabolisme et Prévention des Maladies Cardio-vasculaires [CHU Pitié-Salpêtrière]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Source :
Journal of Virology, Journal of Virology, American Society for Microbiology, 2010, 84 (1), pp.34-43. ⟨10.1128/JVI.02199-08⟩, Journal of Virology, 2010, 84 (1), pp.34-43. ⟨10.1128/JVI.02199-08⟩
Publication Year :
2010

Abstract

Scavenger receptor class B type I (SR-BI) is an essential receptor for hepatitis C virus (HCV) and a cell surface high-density-lipoprotein (HDL) receptor. The mechanism of SR-BI-mediated HCV entry, however, is not clearly understood, and the specific protein determinants required for the recognition of the virus envelope are not known. HCV infection is strictly linked to lipoprotein metabolism, and HCV virions may initially interact with SR-BI through associated lipoproteins before subsequent direct interactions of the viral glycoproteins with SR-BI occur. The kinetics of inhibition of cell culture-derived HCV (HCVcc) infection with an anti-SR-BI monoclonal antibody imply that the recognition of SR-BI by HCV is an early event of the infection process. Swapping and single-substitution mutants between mouse and human SR-BI sequences showed reduced binding to the recombinant soluble E2 (sE2) envelope glycoprotein, thus suggesting that the SR-BI interaction with the HCV envelope is likely to involve species-specific protein elements. Most importantly, SR-BI mutants defective for sE2 binding, although retaining wild-type activity for receptor oligomerization and binding to the physiological ligand HDL, were impaired in their ability to fully restore HCVcc infectivity when transduced into an SR-BI-knocked-down Huh-7.5 cell line. These findings suggest a specific and direct role for the identified residues in binding HCV and mediating virus entry. Moreover, the observation that different regions of SR-BI are involved in HCV and HDL binding supports the hypothesis that new therapeutic strategies aimed at interfering with virus/SR-BI recognition are feasible.

Details

Language :
English
ISSN :
0022538X and 10985514
Database :
OpenAIRE
Journal :
Journal of Virology, Journal of Virology, American Society for Microbiology, 2010, 84 (1), pp.34-43. ⟨10.1128/JVI.02199-08⟩, Journal of Virology, 2010, 84 (1), pp.34-43. ⟨10.1128/JVI.02199-08⟩
Accession number :
edsair.doi.dedup.....cbd207cd9c9dfc5f87ee7f7aae02532c
Full Text :
https://doi.org/10.1128/JVI.02199-08⟩